Carregant...
The systemic implication of novel non-statin therapies in cardiovascular diabetology: PCSK9 as a case model
PCSK9, like other novel non-statin drugs were primarily developed to help patients achieve low-density lipoprotein cholesterol targets, especially in patients with dyslipidemia not achieving lipid goals with statins due to poor tolerance or inadequate response. PCSK9 inhibitors, in addition to modul...
Guardat en:
| Publicat a: | Cardiovasc Endocrinol Metab |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Wolters Kluwer Health
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7673769/ https://ncbi.nlm.nih.gov/pubmed/33225229 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/XCE.0000000000000204 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|